サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1654645

バイオプロセス自動化・制御ソフトウェアの世界市場（2025年～2033年）

Global Bioprocess Automation and Control Software Market - 2025-2033

出版日
ページ情報
英文 179 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
バイオプロセス自動化・制御ソフトウェアの世界市場（2025年～2033年）
出版日: 2025年02月13日
発行: DataM Intelligence
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のバイオプロセス自動化・制御ソフトウェアの市場規模は、2024年に16億米ドルに達し、2033年には27億米ドルに達すると予測され、予測期間2025年～2033年のCAGRは6.2%で成長する見通しです。

バイオプロセス自動化・制御ソフトウェアは、バイオテクノロジー、医薬品、バイオ製造などの産業におけるバイオプロセスの様々な段階を自動化、監視、制御するために設計されたソフトウェアの専門カテゴリーです。これらのソフトウェアシステムは、細胞培養や発酵から下流の精製や品質管理まで、複雑なバイオプロセスのワークフローを最適化するために使用されます。バイオプロセス自動化・制御ソフトウェアの主な目的は、プロセス効率の向上、一貫性の確保、高い製品品質の維持、規制基準の遵守です。

バイオプロセス自動化・制御ソフトウェア市場は、バイオテクノロジー、医薬品、バイオ製造における需要の高まりにより、急速に拡大しています。例えば、OECDによれば、米国はバイオテクノロジー分野で引き続き圧倒的な強さを誇っており、最も活発なバイオテクノロジー企業（2,840社）を擁し、研究開発強度の付加価値は17％に達しています。ベルギーのバイオテクノロジー研究開発付加価値35.7％や、英国の2023年第3四半期の好調は、欧州のイノベーション牽引国としての地位を確固たるものにし、これは不均衡でありつつ有望なバイオテクノロジー環境を示しています。

市場力学：

促進要因と抑制要因

バイオ医薬品と生物製剤の需要増加

バイオ医薬品と生物製剤に対する需要の高まりは、バイオプロセス自動化・制御ソフトウェア市場の成長を大きく牽引しており、予測期間中も牽引していくと予想されます。モノクローナル抗体、細胞・遺伝子治療、ワクチン、遺伝子組換えタンパク質などの製品を含むバイオ医薬品・生物製剤に対する需要の高まりが、バイオプロセス自動化・制御ソフトウェア市場の大きな成長を牽引しています。バイオ医薬品は非常に複雑で繊細な製品であるため、一貫した品質、正確な管理、スケーラビリティが生産の成功に不可欠です。このため、バイオプロセスでは自動化と高度な制御システムが強く推進されています。

例えば、米国研究製薬工業協会（Pharmaceutical Research and Manufacturers of America）によると、2022年末時点で40のバイオシミラー医薬品が承認され、米国では27のバイオシミラー医薬品が上市されています。また、PhRMAが発表したデータによると、世界全体で7,800以上のバイオ医薬品が臨床開発されており、そのうち1,000以上が第3相試験に到達しています。このようなバイオ医薬品や生物製剤に対する需要の高まりが、市場の成長を後押ししています。

サイバーセキュリティへの懸念

サイバーセキュリティへの懸念は、バイオプロセス自動化・制御ソフトウェア市場にとって重要な課題であり、その成長と普及を妨げる可能性があります。バイオ製造施設の自動化システム統合が進むにつれ、クラウドベースのプラットフォーム、IoTデバイス、リアルタイムモニタリングなどのデータ駆動型コネクテッドテクノロジーへの依存が、幅広いサイバーリスクにさらされるようになっています。

例えば、HHSサイバーセキュリティ・プログラムによると、ヘルスケア組織で630件以上、2,900万件の医療記録が侵害されています。これらの脆弱性は、重要なシステムをサイバー攻撃、データ漏洩、業務妨害にさらす可能性があり、製造工程と規制遵守の両方に深刻な結果をもたらす可能性があります。

目次

第1章 市場イントロダクションと範囲

  • レポートの目的
  • 調査のカバー範囲と定義
  • 調査の対象範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • ソフトウェアタイプ別のスニペット
  • 展開方法別のスニペット
  • 用途別のスニペット
  • エンドユーザー別のスニペット
  • 地域別のスニペット

第3章 市場力学

  • 影響要因
    • 促進要因
      • バイオ医薬品と生物製剤の需要増加
      • データ分析と可視化における技術的進歩
    • 抑制要因
      • サイバーセキュリティの懸念
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名な企業
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の研究
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 バイオプロセス自動化・制御ソフトウェア市場：ソフトウェアタイプ別

  • バイオプロセス制御ソフトウェア
    • シングルユースバイオリアクター制御ソフトウェア
    • マルチユースバイオリアクター制御ソフトウェア
  • データ管理および分析ソフトウェア
    • データ統合ソフトウェア
    • データ視覚化ツール
  • 品質管理ソフトウェア（QMS）
  • 検査情報管理システム（LIMS）
    • サンプル管理ソフトウェア
    • 在庫管理
    • ワークフロー管理
  • 製造実行システム
    • 生産追跡ソフトウェア
    • 品質管理モジュール

第6章 バイオプロセス自動化・制御ソフトウェア市場：展開方法別

  • オンプレミス
  • クラウドベース
  • ハイブリッド

第7章 バイオプロセス自動化・制御ソフトウェア市場：用途別

  • 上流処理
    • 細胞培養の自動化
    • 微生物発酵制御
    • 培地調製
    • その他
  • 下流処理
    • 濾過および分離制御
    • クロマトグラフィー制御ソフトウェア
    • その他
  • バイオプロセスモニタリング
  • 研究開発とプロセス開発
  • プロセスの最適化とスケールアップ

第8章 バイオプロセス自動化・制御ソフトウェア市場：エンドユーザー別

  • バイオ医薬品および製薬会社
  • 契約製造企業
  • 学術研究機関
  • 食品・飲料業界
  • その他

第9章 バイオプロセス自動化・制御ソフトウェア市場：地域別の市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢と市場ポジショニング

  • 競合状況の概要と主要な市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第11章 企業プロファイル

  • Thermo Fisher Scientific Inc.
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • Merck KGaA
  • Sartorius AG
  • SECURECELL AG
  • Resea Biotec GmbH
  • Getinge AB
  • Vimachem
  • Danaher Corporation
  • Eppendorf SE
  • Waters Corporation

第12章 前提条件と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証とバリデーション

第13章 付録

目次
Product Code: HCIT9091

The global bioprocess automation and control software market reached US$ 1.6 billion in 2024 and is expected to reach US$ 2.7 billion by 2033, growing at a CAGR of 6.2% during the forecast period 2025-2033.

Bioprocess automation and control software is a specialized category of software designed to automate, monitor and control various stages of bioprocessing in industries such as biotechnology, pharmaceuticals and bio-manufacturing. These software systems are used to optimize complex bioprocess workflows, from cell culture and fermentation to downstream purification and quality control. The primary goal of bioprocess automation and control software is to improve process efficiency, ensure consistency, maintain high product quality and comply with regulatory standards.

The bioprocess automation and control software market is expanding rapidly, driven by rising demand in biotechnology, pharmaceuticals and biomanufacturing. For instance, according to the OECD, the United States continues to be a dominant force in the biotech sector, with the most active biotech businesses (2,840) and an R&D intensity added value of 17%. Belgium's remarkable 35.7% biotech R&D added value or the UK's strong 2023 third quarter, which solidified its position as a European innovation driver, demonstrates an uneven but promising biotechnology environment.

Market Dynamics: Drivers & Restraints

Rising demand for biopharmaceuticals and biologics

The rising demand for biopharmaceuticals and biologics is significantly driving the growth of the bioprocess automation and control software market and is expected to drive over the forecast period. The rising demand for biopharmaceuticals and biologics including products like monoclonal antibodies, cell and gene therapies, vaccines and recombinant proteins drives significant growth in the bioprocess automation and control software market. Biopharmaceuticals are highly complex and sensitive products, making consistent quality, precise control and scalability essential for successful production. This has created a strong push toward automation and advanced control systems in bioprocessing.

For instance, according to the Pharmaceutical Research and Manufacturers of America, as of the end of 2022, 40 biosimilars have been approved and there are 27 biosimilars on the market in the U.S. Additionally, data published by PhRMA indicate that there are more than 7,800 biopharmaceutical products in clinical development globally, of which over 1,000 have reached phase 3 trials. This rising demand for biopharmaceuticals and biologics boosting the market growth.

Cybersecurity concerns

Cybersecurity concerns are a significant challenge for the bioprocess automation and control software market, potentially hindering its growth and adoption. As biomanufacturing facilities increasingly integrate automation systems, the reliance on data-driven, connected technologies such as cloud-based platforms, IoT devices and real-time monitoring opens them up to a wide range of cyber risks.

For instance, according to the HHS Cybersecurity Program, 630+ total healthcare organizational breaches and 29 million healthcare records were breached. These vulnerabilities can expose critical systems to cyberattacks, data breaches and operational disruptions, which can have severe consequences for both the manufacturing process and regulatory compliance.

Segment Analysis

The global bioprocess automation and control software market is segmented based on software type, deployment mode, application, end-user and region.

Software Type:

The bioprocess control software segment is expected to dominate the global bioprocess automation and control software market share

The bioprocess control software segment holds a major portion of the bioprocess automation and control software market share and is expected to continue to hold a significant portion of the market share over the forecast period due to its critical role in optimizing, monitoring and controlling complex biomanufacturing processes. As the demand for biologics and biopharmaceuticals continues to grow, the need for highly precise control systems becomes more vital. Bioprocess control software ensures the accuracy, repeatability and efficiency required to produce high-quality bioproducts while maintaining compliance with stringent regulatory standards.

For instance, Strict control of bioreactor conditions is necessary for the manufacture of monoclonal antibodies (mAbs), as even minor variations might result in decreased output or problems with product quality. Bioprocess control software optimizes the process to attain optimum efficiency by automating the real-time modification of critical variables such as temperature, pH and oxygen concentration.

The quality management software segment is the fastest-growing segment in the bioprocess automation and control software market

The quality management software segment is expected to be the fastest-growing segment in the bioprocess automation and control software market over the forecast period largely driven by the increasing complexity and regulatory scrutiny in the biopharmaceutical and biotechnology sectors. Quality management systems ensure that bioprocesses are executed under controlled conditions, maintain high standards of product quality and comply with stringent regulatory requirements.

For instance, according to the National Institute of Health, in a Quality Benchmarking Study (QBS), more than 200 pharmaceutical manufacturing facilities from across the world contributed information on their production performance and self-evaluations of their compliance with quality standards. These can increase the demand for quality management software in pharmaceutical manufacturing facilities.

Geographical Analysis

North America is expected to hold a significant position in the global bioprocess automation and control software market

North America region is expected to hold the largest share in the bioprocess automation and control software market over the forecast period owing to the rising demand for biopharmaceuticals. The growing shift toward biopharmaceuticals as the preferred treatment option for a variety of diseases is boosting the need for advanced biomanufacturing capabilities. North America especially in the United States and Canada is the largest market and is expected to maintain this position, fueling the demand for bioprocess automation software in the region.

According to the Government of Canada, Canada is the eighth largest pharmaceutical market in the world, with a 2.2% share worldwide. In Canada, brand-name goods make up 25.7% of prescriptions by quantity and 80.5% of sales by value. Generics make up 74.3% of the share by prescriptions and 19.5% of sales by value.

Asia Pacific is growing at the fastest pace in the bioprocess automation and control software market

The Asia Pacific region is experiencing the fastest growth in the bioprocess automation and control software market. The biopharmaceutical market in APAC is experiencing rapid growth, especially in India, Japan and China. The increasing demand for biologics such as monoclonal antibodies, vaccines, biosimilars and gene therapies is driving the need for advanced biomanufacturing solutions, including automation software for both upstream and downstream processing.

For instance, according to Invest India, a total of 22 mergers and acquisitions (M&A) deals have occurred in the life sciences sector in India. The percentage share of the biotechnology segments is biopharmaceuticals at 62%, bioagriculture at 13%, bioindustry at 15% and bioIT & bioservices at 10%.

Competitive Landscape

The major global players in the bioprocess automation and control software market include Thermo Fisher Scientific Inc., Merck KGaA, Sartorius AG, SECURECELL AG, Resea Biotec GmbH, Getinge AB, Vimachem, Danaher Corporation, Eppendorf SE, Waters Corporation and among others.

Emerging Players

The emerging players in the bioprocess automation and control software market include TetraScience, Inc., Korber AG, Infors AG and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Bioprocess Automation and Control Software market report delivers a detailed analysis with 70 key tables, more than 68 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Software Type
  • 2.4. Snippet by Deployment Mode
  • 2.5. Snippet by Application
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Demand for Biopharmaceuticals and Biologics
      • 3.1.1.2. Technological Advancements in Data Analytics and Visualization
    • 3.1.2. Restraints
      • 3.1.2.1. Cybersecurity Concerns
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Bioprocess Automation and Control Software Market, By Software Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Software Type
    • 5.1.2. Market Attractiveness Index, By Software Type
  • 5.2. Bioprocess Control Software*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Single-Use Bioreactor Control Software
    • 5.2.4. Multi-use Bioreactor Control Software
  • 5.3. Data Management and Analytics Software
    • 5.3.1. Data Integration Software
    • 5.3.2. Data Visualization Tools
  • 5.4. Quality Management Software (QMS)
  • 5.5. Laboratory Information Management Systems (LIMS)
    • 5.5.1. Sample Management Software
    • 5.5.2. Inventory Management
    • 5.5.3. Workflow Management
  • 5.6. Manufacturing Execution Systems
    • 5.6.1. Production Tracking Software
    • 5.6.2. Quality Management Modules

6. Bioprocess Automation and Control Software Market, By Deployment Mode

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
    • 6.1.2. Market Attractiveness Index, By Deployment Mode
  • 6.2. On-Premises*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Cloud-Based
  • 6.4. Hybrid

7. Bioprocess Automation and Control Software Market, By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Upstream Processing*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Cell Culture Automation
    • 7.2.4. Microbial Fermentation Control
    • 7.2.5. Media Preparation
    • 7.2.6. Others
  • 7.3. Downstream Processing
    • 7.3.1. Filtration and Separation Control
    • 7.3.2. Chromatography Control Software
    • 7.3.3. Others
  • 7.4. Bioprocess Monitoring
  • 7.5. R&D and Process Development
  • 7.6. Process Optimization and Scale-Up

8. Bioprocess Automation and Control Software Market, By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Biopharmaceutical and Pharmaceutical Companies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Contract Manufacturing Organizations
  • 8.4. Academic and Research Institutes
  • 8.5. Food and Beverage Industry
  • 8.6. Others

9. Bioprocess Automation and Control Software Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Software Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Software Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Software Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Software Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Software Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Mode
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. Thermo Fisher Scientific Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
    • 11.1.5. SWOT Analysis
  • 11.2. Merck KGaA
  • 11.3. Sartorius AG
  • 11.4. SECURECELL AG
  • 11.5. Resea Biotec GmbH
  • 11.6. Getinge AB
  • 11.7. Vimachem
  • 11.8. Danaher Corporation
  • 11.9. Eppendorf SE
  • 11.10. Waters Corporation

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us